 |
 |
Joining the dots Successful cloning depends on proper epigenetic reprogramming of transferred nuclei By Cathy Holding Therapeutic cloning could provide perfectly matched tissues and cells for use in the treatment of a wide range of diseases such as Parkinson's disease, and for the repair of damaged tissues, such as skin grafts to treat severe burns. In addition, constructing embryos from genetically-manipulated nuclei offers the potential for the production of therapeutic agents. However, the process of nuclear transfer to produce cell lines and clones is highly inefficient and the outcome is unpredictable. In the July 1 Current Biology, Fatima Santos and colleagues at the Babraham Institute demonstrate that embryos constructed by the transfer of nuclei from two different cell sources possess nuclei with different epigenotypes that result in different success rates in cloning, and that each of these parameters in the cloned embryos is different from those in the normally fertilized embryo (Current Biology 13:1116-1121, July 1, 2003). Santos et al. visualized the methylation status of individual nuclei in single embryos by using highly sensitive fluorescent antibodies specific to both the methylation and acetylation status of the histone H3 lysine 9, previously shown to be closely linked to the overall methylation and expression status of genes. They compared the frequency of normal and abnormal epigenetic marks between control and cloned embryos, and found a ten-fold difference in the staining between the two groups. In addition they showed that the epigenetic asymmetry resulting from reprogramming in lineage-delineated control blastocysts failed to occur in the cloned embryos. By examining the epigenotypes of cells derived from relatively more-differentiated fibroblasts and those from less-differentiated granulosa cells, they observed that significantly more of the latter cells had normal methylation patterns, with nearly twice as many achieving blastocysts. "Our results strongly suggest that, for cloned embryos, epigenetic variations in donor cells along with partial reprogramming results in heterogeneity of epigenetic marking, which is responsible for their developmental potential," conclude the authors. Links for this article: A. Colman, A. Kind, "Therapeutic cloning: concepts and practicalities." Trends in Biotechnology, 18:5:192-196, 2000. [PubMed Abstract] W. Rideout et al., "Generation of mice from wild-type and targeted ES cells by nuclear cloning," Nature Genetics 24:109- 110, 2000. [PubMed Abstract] F. Santos et al., "Epigenetic Marking Correlates with Developmental Potential in Cloned Bovine Preimplantation Embryos." Current Biology 13:1116-1121, July 1, 2003. http://www.current-biology.com/content/article/abstract?uid=PIIS0960982203004196 The Babraham Institute http://www.babraham.ac.uk SOURCE: The Scientist / BioMed Central http://www.biomedcentral.com/news/20030703/01/ * * * ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn